CLINICAL_TRIALS
trial_result
· 2014-08-25
Clinical Trial Update: FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients [Phase 3]
Summary
Phase 3 trial of FK506 (tacrolimus) for steroid non-resistant myasthenia gravis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Astellas Pharma Inc | Conditions: Myasthenia Gravis | Phase 3 | Status: COMPLETED